Drug intelligence / Profile preview

SAL0133

Development stage: Phase 1
Lead developer: Shenzhen Salubris Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SAL0133 is a **small molecule inhibitor of the SARS-CoV-2 3CL protease (3C-like protease, also known as Mpro)**, developed by Shenzhen Salubris Pharmaceuticals for the treatment of COVID-19. The drug is under investigation for its potential to inhibit viral replication by targeting the major protease required for SARS-CoV-2 replication. The compound is being evaluated in clinical trials for safety, tolerability, and pharmacokinetics, specifically in healthy adult volunteers in China, with the primary indication being infectious and respiratory diseases, notably COVID-19[1][3].

Other names: SAL0133SAL-0133SAL 0133

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on SAL0133.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAL0133.

Explore the full profile